Chickenpox: epidemiological risks in modern conditions and immunization tactics


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The modern feature of the course of chickenpox (CP) is that the representatives of different age groups are involved in the epidemic process and initially healthy individuals develop complications and lesions of the central nervous system. Objective. To study the current epidemiological risks for spread of CP and to determine approaches to choosing immunization strategies. Materials and methods. The investigators analyzed the data available in federal statistical monitoring form №. 23 «Information on outbreaks of infectious diseases»; in the epidemiological investigation reports on the foci of infectious diseases; in the 2018-2020 state reports submitted by the Directorates of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, in the Russian Federation’s subjects included in the Ural Federal Districts and Siberian Federal District; in the 2018-2020 state reports «On the state of sanitary and epidemiological welfare of the population in the Russian Federation» and in the 2011-2018 annual reports of healthcare facilities of the Sverdlovsk Region. Epidemiological and statistical studies were used. Results. The epidemiological risks of CP are determined by the possibility of its carrying into social groups, by the emergence of group and outbreak morbidity in organized groups, and by the epidemic spread among the population of municipalities. The key aspect of epidemiological risk management is immunization against CP virus, the tactics of which can be defined as selective, post-exposure and universal. Conclusion. Planned universal vaccination against CP is the most effective preventive measure. At the same time, in anticipation of the National Immunization Program against CP, it is necessary to implement regional immunization programs for risk groups and post-exposure prophylaxis in organized groups.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Svetlana Smirnova

Yekaterinburg Research Institute of Viral Infections, State Research Center of Virology and Biotechnology «Vector», Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Ural State Medical University, Ministry of Health of Russia

Email: smirnova_ss69@mail.ru
Cand. Мed. Sci., Associate Professor, Department of Epidemiology, Social Hygiene and Organization of Sanitary-Epidemiological Service

Lyudmila Vyatkina

Yekaterinburg Research Institute of Viral Infections, State Research Center of Virology and Biotechnology «Vector», Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: ismp@eniivi.ru
Medical Statistician

Ekaterina Stepanova

Yekaterinburg Research Institute of Viral Infections, State Research Center of Virology and Biotechnology «Vector», Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: ismp@eniivi.ru
Medical Epidemiologist

Әдебиет тізімі

  1. World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Week Epidem Rec. 2014; 89: 265-87. https://www.who.int/wer/2014/wer8925.pdf
  2. Сабитов А.У., Фомин В.В., Шарова А.А. Иммунопатогенез ветряной оспы (обзор литературы). Уральский медицинский журнал 2013; (6): 8-14
  3. Baird N.L., Xiaoli Yu, Randall J.C., Don G. Varicella zoster virus (VZV) -human neuron interaction. Viruses 2013; 5(9): 2106-15.
  4. Freer G., Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018; 41(2): 95-105.
  5. Gershon A.A., Breuer J., Cohen J.I., Cohrs R.J., Gershon M. D., Gilden D. et al. Varicella zoster virus infection. Nat. Rev. Dis. Prim. 2015; 1: 150-60.
  6. Gershon A. A., Gershon M. D. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin. Microbiol. Rev. 2013; 26(4): 728-43
  7. Namazova-Baranova L., Md Ahsan Habib, Povey M., Efendieva K., Fedorova O., Fedoseenko M. et al. A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children. Human Vaccines & Immunotherapeutics. doi: 10.1080/21645515.2021.1959148
  8. Зрячкин Н.И., Бучкова Т.Н., Чеботарева Г.И. Осложнения ветряной оспы (обзор литературы). Журнал инфектологии 2017; 9(3): 117-28. doi: 10.22625/2072-6732-2017-9-3-117-128
  9. Nagel M.A. Varicella zoster virus vasculopathy: clinical features and pathogenesis. J. Neurovirol. 2014; 20(2): 157-63.
  10. Chiang F., Panyaping T., Tedesqui G., Sossa D., Costa Leite C., Castillo M. Varicella zoster CNS vascular complications. A report of four cases and literature review. Neuroradiol. J. 2014; 27(3): 327-33.
  11. Gilden D., Nagel M.A. Varicella zoster virus and giant cell arteritis. Curr. Opin. Infect. Dis. 2016; 29(3): 275-9.
  12. Corti M.,Trione N.,Villafane M.F., Risso D., Yampolsky C., Mamanna L. Acute meningoencephalomyelitis due to Varicella-zoster virus in an AIDS patient: report of a case and review of the literature. Rev. Soc. Bras. Med. Trop. 2011; 44(6): 784-6.
  13. Ibrahim W., Elzouki A.N., Husain A., Osman L. Varicella Zoster Aseptic Meningitis: Report of an Atypical Case and Literature Review. Am. J. Case Rep. 2015; 16: 594-7.
  14. Ellis D.L., Barsell A., Riahi R.R., Stumpf B. Varicella zoster virus encephalitis in a patient with disseminated herpes zoster: report and review of the literature. Dermatol.Online J. 2014; 21(3). doi: 10.5070/D3213022994
  15. Amlie-Lefond C., Gilden D. Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults. J. Stroke Cerebrovasc Dis. 2016; 25(7): 1561-9. doi: 10.1016/j.jstro kecerebrovasdis.2016.03.052. PMID: 27138380; PMCID: PMC4912415
  16. Petrun B., Williams V., Brice S. Disseminated varicella-zoster virus in an immunocompetent adult. Dermatol. Online J. 2015; 21(3): 13030/qt3cz2x99b. PMID: 25780980
  17. Baljic R., Hadzovic M., Mehanic S., Lukovac E., Koluder-Cimic N., Baljic I., Imsirovic B. Varicella Pneumonia in a 39-year-old Female in Third Trimester Twin Pregnancy. Mater. Sociomed. 2012; 24(Suppl. 1): 16-7.
  18. Bialas K.M., Swamy G.K., Permar S.R. Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. Perinatol. 2015; 42(1): 61-75. doi: 10.1016/j.clp.2014.10.006
  19. Lamont R.F., Sobel J.D., Carrington D., Mazaki-Tovi S., Kusanovic J.P., Vaisbuch E., Romero R. Varicella Zoster virus (chickenpox) infection in pregnancy. BJOG 2011; 118(10): 1155-62.
  20. March Rosell6 G.A., Eiros Bouza J.M. Nosocomial respiratory viral infection. An. Sist. Sanit. Navar. 2014; 37(2): 265-79.
  21. Смирнова С.С., Южанина Т.С., Степанова Е.А., Степанова Е.А., Рупышева Т.А. Ветряная оспа: риск-ориентированная модель управления эпидемическим процессом. Дальневосточный журнал инфекционной патологии 2020; (39): 63-8.
  22. Смирнова С.С., Южанина Т.С., Вяткина Л.Г., Голубкова А.А., Алимов А.В. Вспышки инфекционных заболеваний в медицинских организациях. Вопросы эпидемиологической диагностики. Преданалитический этап. Эпидемиол. и инф. бол. 2019; 24(5-6): 204-12
  23. Kim S.-H., Park S.H., Choi S.-M., Lee D. Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella Zoster Virus. J. Korean Med. Sci. 2018; 33(36): 252. doi: 10.3346/jkms.2018.33.e252
  24. Lachiewicz A.M., Srinivas M.L. Varicella Zoster virus post-exposure management and prophylaxis: A review. Prev. Med. Rep. 2019; 16: 101-6. DOI:10.1016/j. pmedr.2019.101016
  25. Papaloukas O., Giannouli G., Papaevangelou V. Successes and challenges in varicella vaccine. Ther. Adv. Vaccines 2014; 2(2): 39-55. doi: 10.1177/2051013613515621
  26. Shaw J., Gershon A.A. Varicella Virus Vaccination in the United States. Viral Immunol. 2018; 31(2): 96-103. doi: 10.1089/vim.2017.0136
  27. Varela F. H., Pinto L.A., Scotta M.C. Global impact of varicella vaccination programs. Hum. Vaccin. Immunother. 2019; 15(3): 645- 57. doi: 10.1080/ 21645515.2018.1546525

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>